1.A Case of Pseudomembranous Colitis Associated with Rifampin.
Ji Young PARK ; Joon Seok KIM ; Sun Jong JEUNG ; Myung Sook KIM ; Seok Chan KIM
The Korean Journal of Internal Medicine 2004;19(4):261-265
Pseudomembranous colitis is known to develop with long-term antibiotic administration, but antitubercular agents are rarely reported as a cause of this disease. We experienced a case of pseudomembranous colitis associated with rifampin. The patient was twice admitted to our hospital for the management of frequent bloody, mucoid, jelly-like diarrhea and lower abdominal pain that developed after antituberculosis therapy that included rifampin. Sigmoidoscopic appearance of the rectum and sigmoid colon and mucosal biopsy were compatible with pseudomembranous colitis. The antitubercular agents were discontinued and metronidazole was administered orally. The patient's symptoms were resolved within several days. The antituberculosis therapy was changed to isoniazid, ethambutol and pyrazinamide after a second bout of colitis. The patient had no further recurrence of diarrhea and abdominal pain. We report here on a case of pseudomembranous colitis associated with rifampin.
Aged
;
Aged, 80 and over
;
Antibiotics, Antitubercular/*adverse effects
;
Diarrhea/etiology
;
Enterocolitis, Pseudomembranous/*chemically induced
;
Humans
;
Male
;
Rifampin/*adverse effects
;
Tuberculosis, Pulmonary/drug therapy
2.A Case of Rifampicin associated Pseudomembranous Colitis.
The Korean Journal of Gastroenterology 2004;43(6):376-379
Pseudomembranous colitis is a dangerous but unusual side effect of antibiotics usage. We report a case of pseudomembranous colitis that developed in a 50-year-old female patient with diabetes mellitus during first line anti-tuberculous therapy including rifampicin. The patient was diagnosed with active pulmonary tuberculosis 70 days earlier. On admission, she suffered intermittent abdominal pain and watery diarrhea for 2 weeks. Colonoscopy revealed exudative, punctuate, raised plaques with skip areas or edematous hyperemic mucosa, and histopathologic findings were consistent with pseudomembranous colitis with typical volcano-like exudate. Symptoms improved on treatment with metronidazole. There was no recurrence after reinstitution of the anti-tuberculous agents excluding rifampicin. In patients with persistent diarrhea receiving anti-tuberculosis treatment, rifampicin associated pseudomembranous colitis should always be kept in mind.
Antibiotics, Antitubercular/*adverse effects
;
English Abstract
;
Enterocolitis, Pseudomembranous/*chemically induced/diagnosis/drug therapy
;
Female
;
Humans
;
Middle Aged
;
Rifampin/*adverse effects
;
Tuberculosis, Pulmonary/drug therapy
3.Recurrent neutropenia induced by rifabutin in a renal transplant recipient.
Ji Yeun CHANG ; Eun Gyo JEONG ; Ji Hyun YU ; Byung Ha CHUNG ; Chul Woo YANG
The Korean Journal of Internal Medicine 2014;29(4):532-534
No abstract available.
Antibiotics, Antitubercular/*adverse effects
;
Female
;
Humans
;
Kidney Transplantation/*adverse effects
;
Middle Aged
;
Neutropenia/blood/*chemically induced/diagnosis
;
Opportunistic Infections/microbiology/*prevention & control
;
Recurrence
;
Rifabutin/*adverse effects
;
Severity of Illness Index
;
Time Factors
;
Tuberculosis/microbiology/*prevention & control
4.Rifampicin-Induced Minimal Change Disease Is Improved after Cessation of Rifampicin without Steroid Therapy.
Dong Hyuk PARK ; Sul A LEE ; Hyeon Joo JEONG ; Tae Hyun YOO ; Shin Wook KANG ; Hyung Jung OH
Yonsei Medical Journal 2015;56(2):582-585
There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved complete remission after cessation of rifampicin without undergoing steroid therapy.
Aged
;
Antibiotics, Antitubercular/*adverse effects/therapeutic use
;
Edema/etiology
;
Female
;
Humans
;
Kidney Function Tests
;
Kidney Glomerulus/pathology
;
Nausea/etiology
;
Nephrosis, Lipoid/*chemically induced/pathology
;
Proteinuria
;
Remission Induction
;
Rifampin/*adverse effects/therapeutic use
;
Treatment Outcome
;
Tuberculosis, Pleural/*drug therapy
5.A Case of Pseudomembranous Colitis Associated with Rifampicin Therapy in a Patient with Rectal Cancer and Gastrointestinal Tuberculosis.
Yong Jun CHOI ; Hyung Gil KIM ; Yun Ah CHOI ; Woo Chul JOO ; Dong Wook SON ; Chul Hyun KIM ; Yong Woon SHIN ; Young Soo KIM
The Korean Journal of Gastroenterology 2009;53(1):53-56
Pseudomembranous colitis (PMC) is known to be associated with the administration of antibiotics which alter normal gastrointestinal flora and allow overgrowth of Clostridium difficile. Most cases of rifampicin-induced PMC are seen in patients with pulmonary tuberculosis, but not with gastrointestinal tuberculosis. We report a case of PMC associated with rifampicin therapy in a patient with gastrointestinal tuberculosis. A 65-year-old female patient with rectal cancer and gastrointestinal tuberculosis was admitted due to abdominal pain and diarrhea. She was treated with anti-tuberculosis agents containing rifampicin. On colonoscopic examination, mucoid exudates and yellowish plaque lesions were observed. Anti-tuberculosis agents were stopped, and the patient was treated with metronidazole. Symptoms were relieved and did not recur when all the anti-tuberculosis agents except rifampicin were started again. When a patient complains of abdominal pain or diarrhea while taking rifampicin, the physician should consider the possibility of rifampicin-associated PMC.
Aged
;
Antibiotics, Antitubercular/*adverse effects/therapeutic use
;
Enterocolitis, Pseudomembranous/*diagnosis/etiology/pathology
;
Female
;
Humans
;
Rectal Neoplasms/*complications/diagnosis
;
Rifampin/*adverse effects/therapeutic use
;
Sigmoidoscopy
;
Tuberculosis, Gastrointestinal/complications/diagnosis/*drug therapy
6.Metabonomic profile of urine from rats administrated with different treatment period of rifampin.
Yan LIAO ; Shuang-Qing PENG ; Xian-Zhong YAN ; He-Bing CHEN ; Li-Shi ZHANG
Acta Academiae Medicinae Sinicae 2008;30(6):696-702
OBJECTIVETo study the effect of rifampin (RFP) on the metabonomic profile of rat urine and its relationship with traditional toxicity evaluation of blood biochemical indicators and histopathology.
METHODSThirty-six male Wistar rats were randomly divided into control group, 50 mg/kg RFP group, and 100 mg/kg RFP group, with 12 rats in each group. Rats in each group were given intragastric infusion with a daily dose of 0, 50 mg/kg RFP, and 100 mg/kg RFP for 3, 7, and 14 days, respectively. Then 4 rats in each group were killed on the next day of administration to collect blood samples and liver sample for the determination of blood biochemical indicators and for the pathological analysis of the liver. The urine specimens over 24 hours of each rat were collected before and after each treatment until the rat was killed. 1H nuclear magnetic resonance (1H NMR) spectra of these urine specimens were acquired and subjected to data preprocess and principal component analyses (PCA).
RESULTSThe level of serum total bilirubin of the rat administrated with 100 mg/(kg x d) RFP for 7 days was significantly higher than that of control group (P < 0.05). Mild hepatotoxicity to the rat, treated with RFP of higher dosage (100 mg/kg) and longer duration (14 days), was revealed by the traditional histopathological method. The metabonomic spectra of rat urine in different groups differed from each other; a trajectory bias in determination of rat urine by 1H NMR occurred depending on the administration duration. As demonstrated by 1H NMR spectra of urine in rats treated with RFP, the concentration of urinary citrate and 2-oxoglutarate decreased, along with the remarkable increase of the concentrations of urinary taurine and glucose (compared with those of the control group).
CONCLUSIONSBeing consistent with the results of traditional toxicity evaluation measurements, metabonomic method is more sensitive. The 1H-NMR metabonomic profile of the rat urine is closely related with the duration of RFP. The hepatic toxicity induced by RFP is related to the reduction of energy metabolism in tricarboxylic acid cycle and the perturbation of glucose and lipid metabolism.
Animals ; Antibiotics, Antitubercular ; administration & dosage ; toxicity ; Blood Chemical Analysis ; Drug-Related Side Effects and Adverse Reactions ; Infusions, Parenteral ; Liver ; drug effects ; pathology ; Male ; Metabolomics ; Models, Animal ; Random Allocation ; Rats ; Rats, Wistar ; Rifampin ; administration & dosage ; toxicity ; Urine ; chemistry
7.Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.
Yu Mi LEE ; Kyu Chan HUH ; Soon Man YOON ; Byung Ik JANG ; Jeong Eun SHIN ; Hoon Sup KOO ; Yunho JUNG ; Sae Hee KIM ; Hee Seok MOON ; Seung Woo LEE
Gut and Liver 2016;10(2):250-254
BACKGROUND/AIMS: To determine the incidence and clinical characteristics of tuberculosis (TB) medication-associated Clostridium difficile infection. METHODS: This multicenter study included patients from eight tertiary hospitals enrolled from 2008 to 2013. A retrospective analysis was conducted to identify the clinical features of C. difficile infection in patients who received TB medication. RESULTS: C. difficile infection developed in 54 of the 19,080 patients prescribed TB medication, representing a total incidence of infection of 2.83 cases per 1,000 adults. Fifty-one of the 54 patients (94.4%) were treated with rifampin. The patients were usually treated with oral metronidazole, which produced improvement in 47 of the 54 patients (87%). Twenty-three patients clinically improved with continuous rifampin therapy for C. difficile infection. There were no significant differences in improvement between patients treated continuously (n=21) and patients in whom treatment was discontinued (n=26). CONCLUSIONS: The incidence of C. difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics. It may not be always necessary to discontinue TB medication. Instead, decisions concerning discontinuation of TB medication should be based on TB status.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Infective Agents/therapeutic use
;
Antibiotics, Antitubercular/*adverse effects
;
*Clostridium difficile
;
Enterocolitis, Pseudomembranous/chemically induced/drug therapy/*epidemiology
;
Female
;
Humans
;
Incidence
;
Male
;
Metronidazole/therapeutic use
;
Middle Aged
;
Retrospective Studies
;
Rifampin/*adverse effects
;
Treatment Outcome
;
Tuberculosis/*drug therapy